Owkin, an AI-biotech company specializing in precision medicine, and Proscia, a leader in AI-enabled pathology solutions, have announced a strategic partnership to enhance MSI testing for colorectal cancer (CRC). This collaboration aims to make MSI screening more efficient and accessible, improving patient outcomes. Additionally, the partnership will focus on developing and commercializing further AI solutions for oncology research and diagnosis.
Microsatellite Instability (MSI) is a key genomic biomarker found in many CRC patients, playing a critical role in treatment decisions. MSI-high tumors often respond well to immunotherapy but may not benefit from traditional chemotherapy. Despite its importance, universal MSI screening faces challenges like high costs, limited accessibility, significant tissue requirements, and subjective result interpretation.
To address these challenges, Owkin has developed MSIntuit CRC v2, an AI-powered solution that predicts MSI status from digital pathology images. This innovative approach is faster, more cost-effective, and more accessible than traditional methods like IHC, PCR, and NGS.
Through their partnership, Owkin will integrate MSIntuit CRC v2 with Proscia’s Concentriq, a leading enterprise pathology platform used by major labs worldwide. This integration will expand access to AI-driven diagnostics, streamline pathology workflows, and enhance testing efficiency by reducing turnaround times.
“While MSI screening helps ensure that each patient receives the best course of treatment, it puts added burden on pathologists and laboratories,” said Dr. Thomas Clozel, MD, CEO of Owkin. “We are thrilled to partner with Proscia and execute on our shared vision of harnessing the power of AI to transform medical research and diagnosis. Together, we will expand access to our digital diagnostics for patients globally.”
Click here to read the original news story.